AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25585595 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 4425
Study 25585595 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with patient or family member
Number of subjects: 4425
Study 25585595 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaving a message
Number of subjects: 4425
Study 25585595 — intervention group
Group type: EXPERIMENTAL
Intervention: No contact
Number of subjects: 4425
Study 23958375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg/day)
Number of subjects: 0
Study 23958375 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) chemotherapy
Number of subjects: 0
Study 22308697 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 60
Study 22308697 — intervention group
Group type: COMPARATOR
Intervention: Xuezhikang
Number of subjects: 60
Study 19346501 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Stimulation and Training Program, 45 minutes a day, 2 days a week, for 6 weeks
Number of subjects: 32
Study 19346501 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Stimulation and Training Program
Number of subjects: 32
Study 16442364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 226
Study 16442364 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 226
Study 15309626 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency oscillatory ventilation (HFOV)
Number of subjects: 487
Study 15309626 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 487
Study 11696046 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen immunotherapy (IT)
Number of subjects: 44
Study 11696046 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (PL)
Number of subjects: 44
Study 9385883 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy for acute myocardial infarction
Number of subjects: 40899
Study 9385883 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy for acute myocardial infarction in patients with diabetes
Number of subjects: 40899
Study 9385883 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy for acute myocardial infarction in patients without diabetes
Number of subjects: 40899
Study 8201614 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment
Number of subjects: 93
Study 8201614 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group (no immediate treatment)
Number of subjects: 93
Study 3067303 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol (L)
Number of subjects: 42
Study 3067303 — intervention group
Group type: COMPARATOR
Intervention: captopril (C)
Number of subjects: 42
Study 3067303 — intervention group
Group type: COMPARATOR
Intervention: labetalol (L) and captopril (C)
Number of subjects: 42
Study 30926396 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 30
Study 30926396 — intervention group
Group type: COMPARATOR
Intervention: Nasal dilator (placebo) treatment
Number of subjects: 30
Study 28587582 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Number of subjects: 20
Study 28587582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25331850 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pressure Reduction (BP change from baseline by -34/-21 mm Hg, 10th percentile)
Number of subjects: 19102
Study 25331850 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pressure Increase (BP change from baseline by +20/+10 mm Hg, 90th percentile)
Number of subjects: 19102
Study 23218699 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intravitreal aflibercept (IAI 2Q4)
Number of subjects: 189
Study 23218699 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intravitreal aflibercept (IAI 2Q4 + PRN)
Number of subjects: 189
Study 23218699 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 189
Study 23218699 — intervention group
Group type: COMPARATOR
Intervention: Sham + IAI PRN
Number of subjects: 189
Study 21774626 — intervention group
Group type: EXPERIMENTAL
Intervention: Open patch test with 1% SLS
Number of subjects: 9
Study 21774626 — intervention group
Group type: EXPERIMENTAL
Intervention: 10× TAP
Number of subjects: 9
Study 21774626 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB irradiation with 0.75 MED
Number of subjects: 9
Study 21774626 — intervention group
Group type: EXPERIMENTAL
Intervention: Open patch test with 1% SLS + PT with 0.5% SLS (SLSPT)
Number of subjects: 9
Study 21774626 — intervention group
Group type: EXPERIMENTAL
Intervention: 10× TAP + PT with 0.5% SLS (TAPPT)
Number of subjects: 9
Study 21774626 — intervention group
Group type: EXPERIMENTAL
Intervention: PT with distilled water (DISPT)
Number of subjects: 9
Study 21774626 — intervention group
Group type: COMPARATOR
Intervention: PT with 0.5% SLS (PT)
Number of subjects: 9
Study 21774626 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (no treatment)
Number of subjects: 9
Study 18215801 — intervention group
Group type: EXPERIMENTAL
Intervention: Less Invasive Stabilization System (LISS)
Number of subjects: 84
Study 18215801 — intervention group
Group type: COMPARATOR
Intervention: Classic double plates (DP)
Number of subjects: 84
Study 16842918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 3451
Study 16842918 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 3451
Study 14586180 — intervention group
Group type: EXPERIMENTAL
Intervention: HDFst (constant dialysate K concentration)
Number of subjects: 10
Study 14586180 — intervention group
Group type: EXPERIMENTAL
Intervention: HDFK (decreased dialysate K concentration during session)
Number of subjects: 10
Study 11742432 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg po bid
Number of subjects: 0
Study 11742432 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1200 mg po weekly
Number of subjects: 0
Study 9420127 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of cow's milk protein for 4 months
Number of subjects: 0
Study 9420127 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy
Number of subjects: 0
Study 9420127 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's atopic history
Number of subjects: 0
Study 9420127 — intervention group
Group type: EXPERIMENTAL
Intervention: Father's atopic history
Number of subjects: 0
Study 9420127 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 0
Study 9420127 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant feeding method or number of older siblings
Number of subjects: 0
Study 8237310 — intervention group
Group type: EXPERIMENTAL
Intervention: Beveled margins of cavity preparations
Number of subjects: 52
Study 8237310 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of etched butt-joint cavities with NPG-GMA/ethanol, re-etching, and surface coating with low viscous resin
Number of subjects: 52
Study 8237310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of restorations
Number of subjects: 52
Study 8237310 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 52
Study 8237310 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients consuming alcoholic beverages
Number of subjects: 52
Study 3566598 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 60
Study 3566598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3566598 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol and Placebo (both groups)
Number of subjects: 60
Study 3566598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpseudophakic eyes
Number of subjects: 60
Study 30489424 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR (17β-estradiol and natural progesterone)
Number of subjects: 0
Study 30489424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27378556 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan (HY) injections
Number of subjects: 22
Study 27378556 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control) injection
Number of subjects: 22
Study 25891749 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline urinary biomarker Coll2‐1NO2 (uColl2‐1NO2)
Number of subjects: 254
Study 25891749 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up urinary biomarker Coll2‐1NO2 at 2.5 years
Number of subjects: 254
Study 25891749 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in urinary biomarker Coll2‐1NO2 over 2.5 years
Number of subjects: 254
Study 24195796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral irradiation with 660 nm laser
Number of subjects: 60
Study 24195796 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral irradiation with 660 nm laser
Number of subjects: 60
Study 24195796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral irradiation with 808 nm laser
Number of subjects: 60
Study 24195796 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral irradiation with 808 nm laser
Number of subjects: 60
Study 24195796 — intervention group
Group type: COMPARATOR
Intervention: No irradiation
Number of subjects: 60
Study 21130544 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula containing canola oil
Number of subjects: 0
Study 21130544 — intervention group
Group type: COMPARATOR
Intervention: Infant formula without canola oil (control)
Number of subjects: 0
Study 18671297 — intervention group
Group type: EXPERIMENTAL
Intervention: PTNS
Number of subjects: 30
Study 18671297 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 30
Study 16554400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section
Number of subjects: 24
Study 16554400 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of suitable studies
Number of subjects: 24
Study 15180667 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-level hierarchical mixed model
Number of subjects: 0
Study 11774933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg tablet dissolved in water)
Number of subjects: 8
Study 9269706 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg/day fixed dose or titrated up to 40 mg/day)
Number of subjects: 153
Study 9269706 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 153
Study 9269706 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 153
Study 9269706 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 153
Study 8003922 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal/Parietal Junction (T/P) lesions
Number of subjects: 16
Study 8003922 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior Parietal Lobe (IPL) lesions
Number of subjects: 16
Study 8003922 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16
Study 3501644 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 68
Study 3501644 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 30028241 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected intensity exercise
Number of subjects: 53
Study 30028241 — intervention group
Group type: COMPARATOR
Intervention: Prescribed intensity exercise
Number of subjects: 53
Study 27388815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance
Number of subjects: 185
Study 27388815 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CT) guidance
Number of subjects: 185
Study 24749812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 142
Study 24749812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 22271480 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles of escalated BEACOPP followed by two cycles of ABVD (2 + 2)
Number of subjects: 1528
Study 22271480 — intervention group
Group type: COMPARATOR
Intervention: Four cycles of ABVD
Number of subjects: 1528
Study 20486463 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquor carbonis distillate (LCD) solution 15%
Number of subjects: 0
Study 20486463 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene cream 0.005%
Number of subjects: 0
Study 18852661 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 0
Study 16061591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg per day for 1 week)
Number of subjects: 287
Study 16061591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 12352275 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day hydroxychloroquine
Number of subjects: 61
Study 12352275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 12352275 — intervention group
Group type: EXPERIMENTAL
Intervention: Open treatment with hydroxychloroquine
Number of subjects: 61
Study 10079451 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.1 mm BENT scleral incision
Number of subjects: 29
Study 10079451 — intervention group
Group type: COMPARATOR
Intervention: 4.1 mm plus meridian corneal incision (PMCI)
Number of subjects: 29
Study 8616476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin-19 serum levels in NSCLC patients
Number of subjects: 116
Study 8616476 — intervention group
Group type: COMPARATOR
Intervention: Cytokeratin-19 serum levels in healthy volunteers
Number of subjects: 116
Study 8616476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin-19 serum levels in NSCLC patients by disease stage
Number of subjects: 116
Study 8616476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin-19 serum levels in NSCLC patients by performance status
Number of subjects: 116
Study 1620909 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation method by inexperienced reader
Number of subjects: 539
Study 1620909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen method by inexperienced reader
Number of subjects: 539
Study 1620909 — intervention group
Group type: COMPARATOR
Intervention: Palpation method by experienced reader
Number of subjects: 539
Study 1620909 — intervention group
Group type: COMPARATOR
Intervention: Pen method by experienced reader
Number of subjects: 539
Study 6367245 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol (400 mg/day)
Number of subjects: 20
Study 6367245 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin (4 mg/day)
Number of subjects: 20
Study 6367245 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prazosin and acebutolol
Number of subjects: 20
Study 6367245 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study 30481269 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent, Russian-backbone, live, attenuated influenza vaccine (LAIV)
Number of subjects: 300
Study 30481269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 29946855 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk non-survivors (LN)
Number of subjects: 48
Study 29946855 — intervention group
Group type: COMPARATOR
Intervention: Low-risk survivors (LS)
Number of subjects: 48
Study 29946855 — intervention group
Group type: COMPARATOR
Intervention: High-risk non-survivors (HN)
Number of subjects: 48
Study 29946855 — intervention group
Group type: COMPARATOR
Intervention: High-risk survivors (HS)
Number of subjects: 48
Study 24118165 — intervention group
Group type: EXPERIMENTAL
Intervention: Active magnetic stimulation (25-min sessions, twice a week, 560 mT peak at 10 Hz)
Number of subjects: 151
Study 24118165 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (5-s 'on'-5-s 'off' pulsing, 20.4% intensity at 1 Hz)
Number of subjects: 151
Study 24118165 — intervention group
Group type: EXPERIMENTAL
Intervention: Active magnetic stimulation
Number of subjects: 151
Study 24118165 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 151
Study 23077532 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 (2-dose group)
Number of subjects: 188
Study 23077532 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 (2+1-dose group)
Number of subjects: 188
Study 23077532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PCV7)
Number of subjects: 188
Study 19721018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet (<50% of daily calories from carbohydrates) (n = 108)
Number of subjects: 215
Study 19721018 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (<30% of daily calories from fat) (n = 107)
Number of subjects: 215
Study 16708233 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal instrumentation (Group 1)
Number of subjects: 22
Study 16708233 — intervention group
Group type: COMPARATOR
Intervention: Ventral instrumentation (Group 2)
Number of subjects: 22
Study 15224630 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (BANS) 128 micrograms b.i.d. for 20 weeks
Number of subjects: 167
Study 15224630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 11295925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional mumps antiserum
Number of subjects: 115
Study 11295925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Candida antiserum
Number of subjects: 115
Study 11295925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (for immune individuals)
Number of subjects: 115
Study 11295925 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy (for anergic patients)
Number of subjects: 115
Study 11295925 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (combined results)
Number of subjects: 115
Study 11295925 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (with complete resolution)
Number of subjects: 115
Study 9508171 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD plus low-dose regional (extended-field) radiation therapy (EF RT)
Number of subjects: 111
Study 9508171 — intervention group
Group type: COMPARATOR
Intervention: MOPP/ABVD
Number of subjects: 111
Study 7836219 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion at 32 degrees C (below thermoneutral)
Number of subjects: 8
Study 7836219 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion at 34.5 degrees C (thermoneutral)
Number of subjects: 8
Study 7836219 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion at 36 degrees C (above thermoneutral)
Number of subjects: 8
Study 7836219 — intervention group
Group type: EXPERIMENTAL
Intervention: All immersion conditions
Number of subjects: 8
Study 7836219 — intervention group
Group type: COMPARATOR
Intervention: Air control at 28 degrees C
Number of subjects: 8
Study 3078521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg daily (n = 200)
Number of subjects: 400
Study 3078521 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 200 mg daily (n = 200)
Number of subjects: 400
Study 28411330 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative Yoga (RY) intervention, n = 18
Number of subjects: 33
Study 28411330 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group, n = 15
Number of subjects: 33
Study 28298397 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model using clinical variables (age, BMI, Epworth sleepiness scale, peak troponin levels, use of calcium antagonists)
Number of subjects: 978
Study 28298397 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model using clinical variables (age, BMI, blood triglycerides, peak troponin levels, Killip class ≥II)
Number of subjects: 978
Study 25783765 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (SET)
Number of subjects: 20
Study 25783765 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 25783765 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (reference group)
Number of subjects: 20
Study 23545907 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (salicylic acid, capryloyl salicylic acid, HEPES, glycolic acid, citric acid, dioic acid)
Number of subjects: 0
Study 23545907 — intervention group
Group type: COMPARATOR
Intervention: Treatment B (BenzaClin®, clindamycin 1% and benzoyl peroxide 5% gel)
Number of subjects: 0
Study 20688209 — intervention group
Group type: EXPERIMENTAL
Intervention: In-lab 600-mg clopidogrel loading dose
Number of subjects: 409
Study 20688209 — intervention group
Group type: COMPARATOR
Intervention: Routine 6-h pre-load with 600-mg clopidogrel
Number of subjects: 409
Study 18635268 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylcholine-coated tympanostomy tubes (TT)
Number of subjects: 70
Study 18635268 — intervention group
Group type: COMPARATOR
Intervention: Uncoated tympanostomy tubes (TT)
Number of subjects: 70
Study 16629428 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurophysiologically based physiotherapy
Number of subjects: 112
Study 16629428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 112
Study 16629428 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (neurophysiologically based physiotherapy and aerobic training)
Number of subjects: 112
Study 16629428 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in habits)
Number of subjects: 112
Study 14682154 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (orally)
Number of subjects: 25
Study 14682154 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin/sulbactam (intravenously)
Number of subjects: 25
Study 10835097 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant massage
Number of subjects: 58
Study 10835097 — intervention group
Group type: COMPARATOR
Intervention: Crib vibrator
Number of subjects: 58
Study 9246168 — intervention group
Group type: EXPERIMENTAL
Intervention: Double freeze-thaw cycle (30 seconds each)
Number of subjects: 113
Study 9246168 — intervention group
Group type: COMPARATOR
Intervention: Single freeze-thaw cycle (30 seconds)
Number of subjects: 113
Study 1430670 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (200-300 mg daily)
Number of subjects: 115
Study 1430670 — intervention group
Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 115